IperionX prices $50M ADS public offering

IperionX Limited is conducting an underwritten public offering of 2,275,000 American Depositary Shares at $21.98 per ADS, for aggregate gross proceeds of about $50 million before fees and expenses.

Rhea-AI Filing Summary

IperionX Limited is conducting an underwritten public offering of 2,275,000 American Depositary Shares at $21.98 per ADS, for aggregate gross proceeds of about $50 million before fees and expenses. Each ADS represents 10 ordinary shares, totaling 22,750,000 ordinary shares.

The offering is led by U.S. institutional investors and is expected to close on July 9, 2026, subject to customary conditions. IperionX plans to use the proceeds to commercialize and scale its titanium and metal alloy production technologies, expand its Titanium Manufacturing Campus in Virginia, advance the Camden-Titan Project in Tennessee, and for general corporate purposes. Cantor Fitzgerald is sole book-running manager, with Roth Capital Partners and B. Riley Securities as co-managers.

Insights

Equity Capital Markets Analyst

IperionX raises $50M via ADS offering to fund titanium expansion.

IperionX has priced an underwritten public offering of 2,275,000 American Depositary Shares at $21.98 per ADS, targeting gross proceeds of about $50 million. Each ADS equals 10 ordinary shares, so 22,750,000 ordinary shares will be issued under existing placement capacity.

The cash is earmarked for commercialization and scale-up of titanium and metal alloy production technologies, including expansion of the Titanium Manufacturing Campus in Virginia and development of the Camden-Titan Project in Tennessee, plus general corporate purposes. This links the raise directly to growth and project build-out rather than refinancing.

The offering uses an already effective shelf registration statement on Form F-3 and is expected to close on July 9, 2026, subject to customary closing conditions. Cantor Fitzgerald acts as sole book-running manager, with Roth and B. Riley as co-managers. Actual impact for shareholders will depend on execution of these projects and how efficiently the new capital is deployed.

Key Figures

ADSs offered: 2,275,000 ADSs Offer price per ADS: $21.98 per ADS Gross proceeds: approximately $50 million +3 more

6 metrics

ADSs offered 2,275,000 ADSs Underwritten public offering size

Offer price per ADS $21.98 per ADS Public offering price

Gross proceeds approximately $50 million Aggregate gross proceeds before fees

Ordinary shares underlying ADSs 22,750,000 ordinary shares Shares represented by 2,275,000 ADSs

Shelf registration file number 333-273519 Form F-3 effective August 9, 2023

Expected closing date July 9, 2026 Anticipated offering completion date

Key Terms

American Depositary Shares, underwritten public offering, shelf registration statement, prospectus supplement, +2 more

6 terms

American Depositary Shares financial

"public offering of 2,275,000 of its American Depositary Shares"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

underwritten public offering financial

"announced the pricing of an underwritten public offering of 2,275,000"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

shelf registration statement regulatory

"A shelf registration statement on Form F-3 (File No. 333-273519) was filed"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

prospectus supplement regulatory

"The Public Offering is being made only by means of a prospectus supplement and accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

placement capacity financial

"ordinary shares that are to represent the ADSs will be issued using the Company’s placement capacity"

Placement capacity is the amount of new shares or other securities a company and its brokers can sell privately to chosen investors at one time. It matters to investors because it determines how much capital the company can raise quickly without a public offering, and larger placements can dilute existing shareholders’ ownership or change the stock’s supply; think of it as the size of a private crowdfunding bucket that can alter who owns the company and how much each share is worth.

Listing Rule 7.1 regulatory

"issued using the Company’s placement capacity in accordance with Listing Rule 7.1"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is IperionX (IPX) raising through its new public offering?

IperionX is raising about $50 million in gross proceeds through an underwritten public offering of 2,275,000 American Depositary Shares. Each ADS represents 10 ordinary shares, so 22,750,000 ordinary shares will be issued using the company’s existing placement capacity.

At what price is IperionX (IPX) offering its American Depositary Shares?

IperionX priced the offering at $21.98 per American Depositary Share. With 2,275,000 ADSs being sold, this pricing results in aggregate gross proceeds of approximately $50 million before underwriting discounts, commissions, and estimated offering expenses payable by the company.

How will IperionX (IPX) use the proceeds from the $50 million ADS offering?

IperionX plans to use proceeds to scale its titanium technologies, including expanding its Titanium Manufacturing Campus in Virginia, advancing the Camden-Titan Project in Tennessee, supporting titanium metal research and development, and funding general corporate purposes linked to its growth initiatives.

When is IperionX’s (IPX) ADS public offering expected to close?

The IperionX ADS offering is expected to close on July 9, 2026, subject to customary closing conditions. The transaction was led by U.S. institutional investors, with Cantor Fitzgerald as sole book-running manager and Roth Capital Partners and B. Riley Securities as co-managers.

What securities structure is IperionX (IPX) using in this capital raise?

IperionX is issuing American Depositary Shares, each representing 10 ordinary shares. The offering covers 2,275,000 ADSs, corresponding to 22,750,000 ordinary shares issued under the company’s placement capacity in accordance with Listing Rule 7.1.

Under what registration is IperionX’s (IPX) public offering being conducted?

The offering is being made under an effective shelf registration statement on Form F-3, File No. 333-273519. A prospectus supplement and accompanying prospectus filed with the SEC and ASX provide detailed terms and access for potential investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/09/2026 - 04:15 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of July, 2026

Commission File Number: 001-41338

IperionX Limited

(Translation of registrant’s name into English)

1092 Confroy Drive

South Boston, Virginia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40‑F.

Form 20-F  ☒    Form 40-F  ☐

Exhibits 1.1 and 5.1 to this Report on Form 6-K are hereby incorporated by reference into IperionX Limited’s Registration Statements on Form F-3 (File No. 333-273519) and on Form S-8 (File No. 333-267088), to the extent not superseded by documents or reports subsequently filed by us under the U.S. Securities Act of 1933 or the U.S. Securities Exchange Act of 1934, in each case as amended.

EXHIBIT INDEX

The following exhibits are filed as part of this Form 6-K:

Exhibit		Description
1.1		Underwriting Agreement, dated July 7, 2026, between IperionX Limited and Cantor Fitzgerald & Co., as representative of the several underwriters named therein
5.1		Opinion of Thomsons on matters of Australian law to IperionX Limited, dated July 9, 2026
99.1		Press Release, dated July 7, 2026

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IperionX Limited
	(registrant)
Date: July 9, 2026	By:	/s/ Marcela Castro

	Name:	Marcela Castro
	Title:	Chief Financial Officer

Exhibit 99.1

IperionX Announces Pricing of Public Offering of American Depositary Shares

South Boston, VA, July 7, 2026 - IperionX Limited (“IperionX” or the “Company”) (Nasdaq:IPX; ASX:IPX) today announced the pricing of an underwritten public offering of 2,275,000 of its American Depositary Shares (“ADSs”), with each ADS representing 10 of its ordinary shares (“Public Offering”), at a price per ADS to the public of $21.98, for aggregate gross proceeds of approximately $50 million, before deducting underwriting discounts, commission and estimated offering expenses payable by the Company. The Public Offering was led by U.S. institutional investors and is expected to close on July 9, 2026, subject to customary closing conditions.

Proceeds from the Public Offering will be used to continue the commercialization and scale-up of certain of our titanium and metal alloy production technologies, including continued scale-up and expansion of the Company’s Titanium Manufacturing Campus in Virginia and associated titanium metal research and development activities, continued development of the Camden-Titan Project in Tennessee, and for general corporate purposes.

Cantor is acting as sole book-running manager for the Public Offering. Roth Capital Partners and B. Riley Securities are acting as co-managers for the Public Offering.

A shelf registration statement on Form F-3 (File No. 333-273519) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on July 28, 2023 and declared effective on August 9, 2023. The Public Offering is being made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus related to the Public Offering was filed with the SEC and is available on the SEC’s website at http://www.sec.gov and on the ASX’s website at http://www.asx.com.au. A final prospectus supplement related to the Public Offering will be filed with the SEC and made available on the SEC’s website at http://www.sec.gov and on the ASX’s website at http://www.asx.com.au. Copies of the final prospectus supplement, when available, and the accompanying prospectus relating to the Public Offering may be obtained from Cantor, Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, Email: prospectus@cantor.com.

The 22,750,000 ordinary shares that are to represent the ADSs will be issued using the Company’s placement capacity in accordance with Listing Rule 7.1.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.

Forward-Looking Statements

This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “anticipate”, “believe”, “expect”, “estimate”, “may”, “will”, “could”, “leading”, “intend”, “contemplate”, “shall” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements with respect to the anticipated closing date of the Public Offering and the anticipated use of proceeds from the Public Offering. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Factors that may cause such differences include, but are not limited to: prevailing market conditions, whether or not the Company will be able to consummate the Public Offering; management’s broad discretion in the use of proceeds from any sale of ADSs; and risks related to the other matters described in the section titled “Risk Factors” in the Company’s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

About IperionX

IperionX aims to be a leading American titanium metal and critical materials company – using patented titanium technologies to produce high performance titanium alloys, from titanium minerals or scrap titanium, at lower energy, cost and carbon emissions. IperionX’s award-winning patented technology portfolio enables high strength forged titanium alloy products at low cost, with class-leading sustainability and superior process energy efficiencies when compared to current industry methods such as the Kroll process. Using its technologies, IperionX has now transitioned to be a growing commercial producer of titanium metal products in the United States.

IperionX produces low-cost and high-quality angular and spherical titanium powder, which is used to produce near-net-shape and final titanium parts through powder metallurgy or additive manufacturing. These technologies provide IperionX with a sustainable competitive advantage and significant value uplift from upgrading raw titanium materials through to finished high-performance titanium products when compared to traditional titanium industry supply chains.

For further information, contact:

T: +1 980 237 8900

E: info@iperionx.com

Filing Exhibits & Attachments

3 documents

Press Releases

• EX-99.1 EXHIBIT 99.1 8.4 KB

Other Documents

• EX-1.1 EXHIBIT 1.1 227.7 KB
• EX-5.1 EXHIBIT 5.1 31.4 KB